AU2079901A - Thrombopoietin mimetics - Google Patents

Thrombopoietin mimetics

Info

Publication number
AU2079901A
AU2079901A AU20799/01A AU2079901A AU2079901A AU 2079901 A AU2079901 A AU 2079901A AU 20799/01 A AU20799/01 A AU 20799/01A AU 2079901 A AU2079901 A AU 2079901A AU 2079901 A AU2079901 A AU 2079901A
Authority
AU
Australia
Prior art keywords
mammal
invented
thrombopoietin mimetics
mimetics
thrombopoietin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU20799/01A
Other languages
English (en)
Inventor
Kevin J. Duffy
Juan I. Luengo
Alan T. Price
Lihua Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2079901A publication Critical patent/AU2079901A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU20799/01A 1999-12-06 2000-12-06 Thrombopoietin mimetics Abandoned AU2079901A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16913099P 1999-12-06 1999-12-06
US60169130 1999-12-06
PCT/US2000/033432 WO2001039773A1 (en) 1999-12-06 2000-12-06 Thrombopoietin mimetics

Publications (1)

Publication Number Publication Date
AU2079901A true AU2079901A (en) 2001-06-12

Family

ID=22614367

Family Applications (1)

Application Number Title Priority Date Filing Date
AU20799/01A Abandoned AU2079901A (en) 1999-12-06 2000-12-06 Thrombopoietin mimetics

Country Status (7)

Country Link
EP (1) EP1244446B1 (enExample)
JP (1) JP2003515560A (enExample)
AT (1) ATE344031T1 (enExample)
AU (1) AU2079901A (enExample)
DE (1) DE60031714T2 (enExample)
ES (1) ES2275567T3 (enExample)
WO (1) WO2001039773A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851503B2 (en) 2002-08-14 2010-12-14 Nissan Chemical Industries, Ltd. Thrombopoetin receptor activator and process for producing the same
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
CN100513398C (zh) 2002-12-03 2009-07-15 Axys药物公司 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
US20060084682A1 (en) * 2002-12-13 2006-04-20 Heerding Dirk A Thrombopoietin mimetics
TW200418791A (en) * 2003-01-23 2004-10-01 Bristol Myers Squibb Co Pharmaceutical compositions for inhibiting proteasome
KR20060079190A (ko) * 2003-08-14 2006-07-05 아사히 가세이 파마 가부시키가이샤 치환 아릴알칸산 유도체 및 그의 용도
US8729117B2 (en) 2004-06-02 2014-05-20 Pharmacyclics, Inc. Factor VIIa inhibitor
WO2006062240A1 (en) 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
KR101215207B1 (ko) 2004-12-14 2012-12-26 닛산 가가쿠 고교 가부시키 가이샤 아미드 화합물 및 트롬보포이에틴 리셉터 활성화제
EP1910338B1 (en) * 2005-07-14 2010-08-25 Irm, Llc Heterotetracyclic compounds as tpo mimetics
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
JP5104752B2 (ja) 2005-07-20 2012-12-19 日産化学工業株式会社 ピラゾール化合物及びトロンボポエチンレセプター活性化剤
RU2385865C2 (ru) * 2005-08-15 2010-04-10 Айрм Ллк Соединения и композиции в качестве миметиков тро
US8026368B2 (en) 2005-11-07 2011-09-27 Nissan Chemical Industries, Ltd. Hydrazide compounds and thrombopoietin receptor activators
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
EP2054405B1 (en) 2006-07-11 2013-09-18 Daewoong Pharmaceutical Co., Ltd. Novel biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same
NZ580662A (en) 2007-04-30 2012-01-12 Abbott Lab Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme used in manufacture of medicament for treatment of diabetes or lipid associated disorders
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
WO2013086436A1 (en) 2011-12-08 2013-06-13 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
SI2807165T1 (sl) 2012-01-27 2019-08-30 Universite De Montreal Pirimido(4,5-B)indol derivati in njihova uporaba pri ekspanziji hematopoetskih matičnih celic
CA2946446C (en) 2014-04-22 2020-11-03 Universite De Montreal Pyrido-pyrrolo-pyrimidine and pyrido-indole compounds, pharmaceutical compositions containing same and their use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells
SG11201703407UA (en) 2014-10-31 2017-05-30 Nissan Chemical Ind Ltd Ligand-binding fiber and cell culture substrate using said fiber

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE193350C (enExample) *
US851444A (en) * 1905-11-13 1907-04-23 Agfa Ag Amido-oxy-sulfonic acid of phenylnaphthimidazol and process of making same.
US4435417A (en) * 1981-02-20 1984-03-06 Gruppo Lepetit S.P.A. Antiinflammatory 3H-naphtho[1,2-d]imidazoles
DE4126612A1 (de) * 1990-08-14 1992-02-20 Ciba Geigy Ag Reaktivfarbstoffe, deren herstellung und verwendung
IE70217B1 (en) * 1990-08-15 1996-10-30 British Bio Technology Benzimidazole derivatives process for their preparation and application

Also Published As

Publication number Publication date
ES2275567T3 (es) 2007-06-16
EP1244446A4 (en) 2003-01-08
WO2001039773A1 (en) 2001-06-07
DE60031714T2 (de) 2007-09-06
JP2003515560A (ja) 2003-05-07
EP1244446A1 (en) 2002-10-02
ATE344031T1 (de) 2006-11-15
EP1244446B1 (en) 2006-11-02
DE60031714D1 (de) 2006-12-14

Similar Documents

Publication Publication Date Title
EP1223944A4 (en) THROMBOPOIETINMIMETIKA
EP1244446A4 (en) Thrombopoietin mimetics
EP1213965A4 (en) Thrombopoietin mimetics
HK1043472A1 (zh) 血小板减少症拟态
WO2002049413A3 (en) Thrombopoietin mimetics
MY136707A (en) Thrombopoietin mimetics
WO2004054515A3 (en) Thrombopoietin mimetics
EP1133291A4 (en) THROMCOCYTOPENIA TREATMENTS
AU2002328972A1 (en) Piperidine derivatives as antibacterial agents
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
AU6825300A (en) Compounds
FI956014A0 (fi) Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon
AU3831301A (en) Method for treating ocular pain
AP2001002291A0 (en) Novel method of treatment.
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
AUPQ866500A0 (en) Therapeutic compounds and methods
IL131478A0 (en) Methods for treatment of scar tissue
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
AU5639700A (en) Targeted anticalcification treatment
AU1618901A (en) Treatment of rosacea
AU4193800A (en) Use of tagatose to enhance key blood factors
TR200003084T2 (tr) Paroxetine askorbat
AU2001253560A1 (en) Methods of treatment
AU5328800A (en) Use of interleukin-11 to treat hemorrhagic shock

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase